Summary:
- This article discusses the potential of the drug elacestrant as a treatment for estrogen receptor (ER)-positive, HER2-negative breast cancer.
- Elacestrant is a selective estrogen receptor degrader (SERD) that can help block the growth and spread of ER-positive breast cancer cells.
- Combining elacestrant with other targeted therapies may be an effective approach to treating this type of breast cancer, as it can help overcome resistance to single-agent treatments.